Rung 4 · Strong
Pembrolizumab with chemotherapy for early triple-negative breast cancer
Longer survival in a large randomized trial.
TreatmentWith your doctor
What studies found
In KEYNOTE-522 (1,174 patients), pembrolizumab given with chemotherapy before surgery and alone after surgery raised five-year overall survival to 86.6% from 81.7% with chemotherapy alone.
The catch
Based on one large trial.
What to do
If you have stage II or III triple-negative breast cancer, ask about it before treatment starts.
Sources
Rung 4 of 5, Strong: At least one large randomized trial, or very large consistent studies, on this exact question. How we score
To take it to your doctor, print this page.
Step by step
For the whole picture, from prevention and screening to treatment and life after, see the breast cancer page.
Related
- CDK4/6 inhibitor after surgery for high-risk hormone-positive breast cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Skipping armpit surgery for small, low-risk breast cancersRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Skipping radiation after lumpectomy at 65 or older (low-risk cancer)Rung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Trastuzumab deruxtecan for HER2-positive breast cancerRung 4 · StrongWith your doctorSafety flagRung 4 · StrongTreatmentWith your doctorSafety flag
- Camizestrant when an ESR1 mutation appears in advanced breast cancerRung 3 · ModerateWith your doctorSafety flagRung 3 · ModerateTreatmentWith your doctorSafety flag